Allarity Therapeutics (FRA:C6D0) Moat Score: 2/10 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C6D0 Allarity Therapeutics Inc FRA:C6D0
26 GF Score
Price €41,491.20
! 2 Warning Signs
View Full Analysis

What is Allarity Therapeutics Moat Score?

Allarity Therapeutics FRA:C6D0 26 Moat Score is 2 as of Jul. 14, 2026. GuruFocus rates FRA:C6D0 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Allarity Therapeutics ranks better than 58.31% on this metric.

Allarity Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Allarity Therapeutics has No Moat: Allarity Therapeutics Inc lacks significant market leadership or customer loyalty. The company does not possess strong intellectual property or patents that provide a durable advantage. Its market presence is limited, and there are no significant regulatory barriers or cost advantages that would suggest a competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Allarity Therapeutics might have No Moat - Very weak/transient advantages.

Allarity Therapeutics  (FRA:C6D0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Allarity Therapeutics Moat Score Related Terms

FRA:C6D0 vs NCEL, LPCN, PTN: Moat Score Comparison

For the Biotechnology subindustry, Allarity Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Allarity Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allarity Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Allarity Therapeutics's Moat Score falls into.


FRA:C6D0
26GF Score
Allarity Therapeutics Inc FRA:C6D0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Allarity Therapeutics (FRA:C6D0) has a Moat Score of 2 as of Jul. 14, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Allarity Therapeutics ranks #582 out of 1396 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Allarity Therapeutics' Moat Score too high?
Allarity Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Allarity Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Allarity Therapeutics ranks #582 out of 1396 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Allarity Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Allarity Therapeutics' Moat Score compare to NCEL and LPCN?
According to the Biotechnology industry distribution chart, Allarity Therapeutics ranks #582 out of 1396 companies for Moat Score. This puts Allarity Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Allarity Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allarity Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allarity Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allarity Therapeutics stock overvalued right now?
Allarity Therapeutics (FRA:C6D0) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Allarity Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Allarity Therapeutics (FRA:C6D0), the current Moat Score is 2 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allarity Therapeutics Business Description

Other Exchanges ALLR:USA
Address 123 East Tarpon Avenue, Tarpon Springs, FL, USA, 34689
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.
26GF Score

Get the complete analysis for FRA:C6D0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41,491.20
Price